Pfizer has recalled multiple injection drugs containing glass particles, but none of them have entered the Chinese market
芊芊551
发表于 2024-1-3 18:20:51
267
0
0
Pfizer has recalled several injection drugs with glass particles, but none of them have entered the Chinese market. The official website of the US Food and Drug Administration (FDA) recently issued two notices, stating that Pfizer has voluntarily recalled products such as 4.2% sodium bicarbonate injection, 8.4% sodium bicarbonate injection, atropine sulfate injection, and bleomycin for injection, due to the presence of glass particles in the aforementioned products. The website of the National Medical Products Administration shows that none of Pfizer's above-mentioned drugs have entered the domestic market.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
You may like
- Pfizer Beijing R&D Center settles in BioPark, Beijing Medical Innovation Park
- Pfizer will make an appearance at the 7th CIIE and make a commitment to its development for the next five years
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
- Exhibits become commodities in seconds! Prostate cancer new drug approved in China, Pfizer Wang Yu: promoting China's new drug market to synchronize with the global market
- Exploring the CIIE | New products from Sinogen, Roche, and Pfizer become highlights of the CIIE
- Pfizer plans to sell hospital drug division, company responds
- After closing factories and laying off employees, Pfizer is reportedly considering selling its hospital drug division
- Pfizer and CR Pharma reach strategic partnership on four mature drugs
- Pfizer expects revenue of $61 billion to $64 billion in 2025, with an estimated $63.23 billion
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy